drugset / Trial / NCT04451200

Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning

NCT04451200 ↗

Phase 2 Not yet recruiting 82 enrolled Institut Paoli-Calmettes
NaSingle-groupOpen-labelTreatment

Summary

Because the anti-leukemic activity of busulfan, this dug is largely used in graft conditioning but in elderly and/or cormobid patienth an excess of toxicity is observed. This study focus on the possibility of significanty reducing this toxicity by customizing the doses of busulfan to individual PK parameters.

Timeline

Start
2020-11
Primary completion
2023-11
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Busulfan Small molecule — Other